Marta Ortega-Ortega

Marta Ortega-Ortega

Auto-generated profile, based on publicly available information

Marta Ortega-Ortega

Department of Applied and Public Economics, and Political Economy, Complutense University of Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2018 in Value in Health
Verified
Journal Article
Closed access
PDF file
DEDavid Epstein
David Epstein
SOSarah Onida
Sarah Onida
RBRoshan Bootun
Roshan Bootun
MOMarta Ortega-Ortega
Marta Ortega-Ortega
ADAlun H. Davies
Alun H. Davies

27 September 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MOMarta Ortega‐Ortega
Marta Ortega‐Ortega
PHPaul A. Hanly
Paul A. Hanly
APAlison Pearce
Alison Pearce
ISIsabelle Soerjomataram
Isabelle Soerjomataram
LSLinda Sharp
Linda Sharp

30 December 2015 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
ASAmanda C. Shepherd
Amanda C. Shepherd
MOMarta Ortega-Ortega
Marta Ortega-Ortega
MGManj S. Gohel
Manj S. Gohel
DEDavid Epstein
David Epstein
LBLouise C. Brown
Louise C. Brown
ADAlun H. Davies
Alun H. Davies
Objectives: Although the clinical benefits of endovenous thermal ablation are widely recognized, few studies have evaluated the health economic implications of different treatments. This study compares 6-month clinical outcomes and cost-effectiveness of endovenous laser ablation (EVLA) compared with radiofrequency ablation (RFA) in the setting of a randomized clinical trial. Methods: Patients with symptomatic primary varicose veins were randomized to EVLA or RFA and followed up for 6 months to evaluate clinical improvements, health related quality of life (HRQOL) and cost-effectiveness. Results: A total of 131 patients were randomized, of which 110 attended 6-month follow-up (EVLA n = 54; RFA n = 56). Improvements in quality of life (AVVQ and SF-12v2) and Venous Clinical Severity Scores (VCSS) achieved at 6 weeks were maintained at 6 months, with no significant difference detected between treatment groups. There were no differences in treatment failure rates. There were small differences in favor of EVLA in terms of costs and 6-month HRQOL but these were not statistically significant. However, RFA is associated with less pain at up to 10 days. Conclusions: EVLA and RFA result in comparable and significant gains in quality of life and clinical improvements at 6 months, compared with baseline values. EVLA is more likely to be cost-effective than RFA but absolute differences in costs and HRQOL are small.

10 April 2023 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
PHPaul A. Hanly
Paul A. Hanly
MOMarta Ortega Ortega
Marta Ortega Ortega
APAlison Pearce
Alison Pearce
MCMarianna de Camargo Cancela
Marianna de Camargo Cancela
ISIsabelle Soerjomataram
Isabelle Soerjomataram
LSLinda Sharp
Linda Sharp

13 May 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
PHPaul A. Hanly
Paul A. Hanly
MOMarta Ortega-Ortega
Marta Ortega-Ortega
ISIsabelle Soerjomataram
Isabelle Soerjomataram
The inclusion of productivity costs can affect the outcome of cost-effectiveness analyses. We estimated the value of cancer premature mortality productivity costs for Europe in 2020 using the Human Capital Approach (HCA) and compared these to the Friction Cost Approach (FCA). Cancer mortality data were obtained from GLOBOCAN 2020 by sex and five-year age groups. Twenty-three cancer sites for 31 European countries were included. The HCA and the FCA were valued using average annual gross wages by sex and age group and applied to Years of Potential Productive Life Lost. 2020 friction periods were calculated and all costs were in 2020 euros. Estimated cancer premature mortality costs for Europe in 2020 were EUR 54.0 billion (HCA) and EUR 1.57 billion (FCA). The HCA/FCA cost ratio for Europe was 34.4, but considerable variation arose across countries (highest in Ireland: 64.5 v lowest in Czech Republic: 11.1). Both the HCA and the FCA ranked lung, breast and colorectal as the top three most costly cancers in Europe, but cost per death altered rankings substantially. Significant cost differences were observed following sensitivity analysis. Our study provides a unique perspective of the difference between HCA and FCA estimates of productivity costs by cancer site and country in Europe.

8 August 2023 in Applied Health Economics and Health Policy
Verified
Journal Article
Open access
PDF file
MOMarta Ortega-Ortega
Marta Ortega-Ortega
PHPaul A. Hanly
Paul A. Hanly
APAlison Pearce
Alison Pearce
ISIsabelle Soerjomataram
Isabelle Soerjomataram
LSLinda Sharp
Linda Sharp
Aim To estimate the potential cost of lost labour productivity due to cancer-related premature mortality in Europe (EU-27 plus Norway, Switzerland, Iceland and United Kingdom) from 2018 to 2040. Methods Deaths and years of potential productive life lost due to 23 types of cancer were estimated for 2018–2040, for 31 European countries. The data were analysed by age groups, by sex and by year. Projected productivity costs were estimated by calculating gross earnings by country, gender and age group using the Human Capital Approach, adjusting for projected labour force participation and unemployment rates. Various data sources were used. Sensitivity analyses were conducted. Results Between 2018 and 2040, cancer is expected to cause around eight million premature deaths (58% male). The cumulative projected productivity costs in this respect are €1.3 trillion, representing an annual average of €58.7 billion, or 0.43% of the EU-27 gross domestic product. Labour productivity costs are projected to decrease by 6% from 2018 to 2040. The highest cost region is Western Europe, where Germany and France will experience the highest cumulative losses (€288 and €192 billion, respectively). The most costly cancers, in terms of total costs related to productivity losses, are of the lung and colorectum (€264.4 and €116.3 billion, respectively). In terms of average productivity cost per death, the most costly forms of cancer are Hodgkin lymphoma (€301,157) and melanoma (€260,522). Conclusion The novel information presented could help national policymakers anticipate possible areas for cost savings. Action should be taken on disease prevention, on reducing mortality and on delaying the age of death due to Hodgkin lymphoma, brain cancer, leukaemia and melanoma. Furthermore, the study findings enhance our understanding of macroeconomic variables and could be useful in determining a re-allocation of health expenditures.